Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

Émeric Boisteau

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1831-6145; OpenAlex author ID A5091700576. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 2

  1. Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyae079↗
  2. Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors. Co-author DOI 10.1177/1758835920937949↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christelle d’Engremont · 1 shared paper, 2020 · strength 0.11
  2. Carole Vitellius · 1 shared paper, 2020 · strength 0.11
  3. Cindy Neuzillet · 1 shared paper, 2020 · strength 0.11
  4. Anthony Turpin · 1 shared paper, 2020 · strength 0.11
  5. Marc Hilmi · 1 shared paper, 2020 · strength 0.11
  6. Mathilde Wisniewski · 1 shared paper, 2020 · strength 0.11
  7. Louis de Mestier · 1 shared paper, 2020 · strength 0.11
  8. Pascal R. Hammel · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.